3-methyl-4-[(E)-2-(5,6,7,8-tetrahydronaphthalen-2-yl)prop-1-enyl]benzoic acid

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 英文名称: 3-methyl-4-[(E)-2-(5,6,7,8-tetrahydronaphthalen-2-yl)prop-1-enyl]benzoic acid
• 化学式: C₂₁H₂₂O₂
• 分子量: 306.4
• InChiKey: HECUDDQWGDNZNF-SDNWHVSQSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.1
• 重原子数：
  23
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

文献信息

• Method of treating cancers with SAHA and pemetrexed
  申请人：Pluda James

  公开号：US20070117815A1

  公开（公告）日：2007-05-24

  The present invention relates to a method of treating cancer in a subject in need thereof, by administering to a subject in need thereof a first amount of a histone deacetylase (HDAC) inhibitor or a pharmaceutically acceptable salt or hydrate thereof, and a second amount of an anti-cancer agent. The HDAC inhibitor and the anti-cancer agent may be administered to comprise therapeutically effective amounts. In various aspects, the effect of the HDAC inhibitor and the anti-cancer agent may be additive or synergistic.

  本发明涉及一种治疗需要的受试者癌症的方法，通过向需要的受试者施用一定量的组蛋白去乙酰化酶（HDAC）抑制剂或其药用可接受的盐或水合物的第一量，以及一定量的抗癌药物。HDAC抑制剂和抗癌药物可以被施用以包含治疗有效量。在各种方面，HDAC抑制剂和抗癌药物的效果可能是相加的或协同的。
• Biomarker combinations for colorectal cancer
  申请人：Diagnoplex

  公开号：EP2544006A1

  公开（公告）日：2013-01-09

  The present invention relates to methods and kits for the detection of predetermined biomarker BIRC4BP for early diagnosis and management of colorectal cancer.

  本发明涉及用于早期诊断和管理结直肠癌的预定生物标志物 BIRC4BP 的检测方法和试剂盒。
• Tumor suppressor gene polypeptides and related nucleic acids, host cells, compositions, and methods of use in inhibition of cell growth, modulation of gene expression, and enhancement of immune-response inducing effect of a vaccine
  申请人：Simmons Perry Denise

  公开号：US20050164943A1

  公开（公告）日：2005-07-28

  A polypeptide consisting essentially of the amino acid sequence NCEHFVTYCRYG (SEQ ID NO: 1), ENCEHFVNELRYG (SEQ ID NO: 2), NCEHFVNELRYG (SEQ ID NO: 3), RNCEHFVAQLRYG (SEQ ID NO: 4), NCEHFVAQLRYG (SEQ ID NO: 5), or NCEHFVTYLRYG (SEQ ID: 6), or a variant of any of the foregoing, a composition comprising same, a nucleic acid consisting essentially of a nucleotide sequence encoding the amino acid sequence of any of SEQ ID NOS: 1-6 or a variant thereof, a composition comprising same, a host cell comprising an above-described nucleic acid molecule, a method of inhibiting cancerous cell growth comprising contacting a collection of cancerous cells with a cell growth-inhibiting effective amount of one or more of the foregoing, a method of modulating gene expression comprising contacting a collection of cells with a gene expression-modulating effective amount of at least one above-described nucleic acid or a composition comprising same, and a method of enhancing the immune response-inducing effect of a vaccine, which method comprises adding to the vaccine at least one above-described polypeptide, or a variant thereof.

  一种基本上由氨基酸序列 NCEHFVTYCRYG（SEQ ID NO: 1）、ENCEHFVNELRYG（SEQ ID NO: 2）、NCEHFVNELRYG（SEQ ID NO: 3）、RNCEHFVAQLRYG（SEQ ID NO: 4）、NCEHFVAQLRYG（SEQ ID NO：5），或 NCEHFVTYLRYG（SEQ ID：6），或上述任何一种的变体，包含相同成分的组合物，基本上由编码 SEQ ID NOS：一种抑制癌细胞生长的方法，包括使癌细胞集合与一种或多种前述物质中抑制细胞生长有效量的物质接触、一种调节基因表达的方法，包括使细胞与调节基因表达有效量的至少一种上述核酸或包含上述核酸的组合物接触，以及一种增强疫苗的免疫应答诱导效应的方法，该方法包括向疫苗中加入至少一种上述多肽或其变体。
• TOPICAL FORMULATIONS OF HISTONE DEACETYLASE INHIBITORS AND METHODS OF USING THE SAME
  申请人：Government of the United States of America, Represented by the Secretary, Department of Health and Human Services

  公开号：EP1924245A2

  公开（公告）日：2008-05-28
• METHODS OF USING SAHA AND ERLOTINIB FOR TREATING CANCER
  申请人：Merck and Co., Inc.

  公开号：EP1942907A2

  公开（公告）日：2008-07-16